Systemic sclerosis & Raynaud's
Interleukin 4-receptor-α blockade in localised scleroderma: a phase 2 proof-of-concept study
Authors' conclusion
Thus, selective inhibition of IL-4/IL-13 prevents the progression of LS and is promising for therapeutic prevention of other fibrosing diseases.
Study context
- Population
- Patients with localised scleroderma (LS)
- Comparison
- Dupilumab for 6 months vs placebo
Methodological detailsphase 2 proof-of-concept
- Phase 2 proof-of-concept
Primary result
As reported in the abstract
Clinical improvement · 6 months
- Significant clinical improvement over placebo
Further findings
Local inflammation · 6 months
- Significant attenuation of the local inflammation
IL-4/IL-13-dependent gene signature · 6 months
- Specific and significant reduction
Genes coding for fibrosis-inducing proteins · 6 months
- Partial suppression
Original publication
Interleukin 4-receptor-α blockade in localised scleroderma: a phase 2 proof-of-concept study. Ann Rheum Dis. Published 29 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →